Holen Sie sich die Stockscreener-App
13.76
0.72%
-0.066
Schlusskurs vom Vortag:
$13.83
Offen:
$13.68
24-Stunden-Volumen:
34,367
Relative Volume:
0.05
Marktkapitalisierung:
$940.22M
Einnahmen:
$568.09M
Nettoeinkommen (Verlust:
$27.27M
KGV:
42.01
EPS:
0.3276
Netto-Cashflow:
$71.41M
1W Leistung:
-4.45%
1M Leistung:
-2.80%
6M Leistung:
+59.47%
1J Leistung:
+88.86%
1-Tages-Spanne:
$13.55
$13.91
1-Wochen-Bereich:
$13.55
$14.50
52-Wochen-Spanne:
$6.255
$15.89
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
13.77 | 944.66M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
106.12 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.82 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.78 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.60 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.46 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | CJS Securities | Market Outperform |
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus Stock Price Forecast. Should You Buy BVS? - StockInvest.us
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Bioventus (NASDAQ:BVS) Gains As Healthcare Demand Supports Growth - Kalkine Media
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (BVS) - TMX Newsfile
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceExhaustion Gap - siam.in
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Bioventus Inc. Class A (BVS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Are Investors Undervaluing Bioventus (BVS) Right Now? - qz.com
Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS - MarketBeat
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - easternprogress.com
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Drops 8.9% to $13.9: Key Support Tested After Sharp SelloffVolume Breakout Ideas - vinanet.vn
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Bioventus Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-08-05 - Seeking Alpha
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket - Investing.com Nigeria
Bioventus (NASDAQ:BVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bioventus Inc. Q2 2026 Earnings: Strong Revenue Growth, Net Income, and Financial Highlights - Minichart
Bioventus Shareholder Action Reminder - TMX Newsfile
Bioventus Inc. Reports Q2 2026 Results and Strategic Review in Latest 10-Q Filing - Kalkine Media
Bioventus Q2 Earnings Call Highlights - MarketBeat
Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed - marketscreener.com
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):